Exelixis, Inc. (NASDAQ:EXEL) Q3 2022 Earnings Conference Call November 1, 2022 5:00 PM ET

Company Participants

Susan Hubbard – Executive Vice President of Public Affairs and Investor Relations

Mike Morrissey – President and Chief Executive Officer

Chris Senner – Chief Financial Officer

P.J. Haley – Executive Vice President-Commercial

Vicki Goodman – Chief Medical Officer

Peter Lamb – Chief Scientific Officer

Conference Call Participants

Asthika Goonewardene – Truist Securities

Michael Schmidt – Guggenheim

Mike King – EF Hutton

Do Kim – Piper Sandler

Silvan Tuerkcan – JMP

Jason Gerberry – Bank of America

Andy Hsieh – William Blair

Jay Olson – Oppenheimer

Etzer Darout – BMO

Peter Lawson – Barclays

Yaron Werber – Cowen

Chris Shibutani – Goldman Sachs

Operator

Good day, ladies and gentlemen, and welcome to the Exelixis’ Third Quarter 2022 Financial Results Conference Call. My name is Chuck, and I’ll be your operator for today. As a reminder, this call is being recorded for replay purposes.

I would now like to turn the call over to your host for today, Ms. Susan Hubbard, Executive Vice President of Public Affairs and Investor Relations. Please go ahead ma’am.

Susan Hubbard

Thank you, Chuck. And thank you all for joining us for the Exelixis’ third quarter 2022 financial results conference call.

Joining me on today’s call are Mike Morrissey, our President and CEO; Chris Senner, our Chief Financial Officer; P.J. Haley, our Executive Vice President of Commercial; Vicki Goodman, our Chief Medical Officer; and Peter Lamb, our Chief Scientific Officer, who together will review our progress for the third quarter 2022 ended June 30, 2022 and subsequent events including the two business development announcements made today.

During the call today, we will refer to financial measures not calculated according to generally accepting accounting principles. Please refer to today’s press release, which is posted on our website for an explanation of our reasons for using such non-GAAP measures as well as tables deriving these measures from our GAAP results.

During the course of this presentation, we will be making forward-looking statements regarding future events and the future performance of the company. This includes statements about possible developments regarding discovery, product development, regulatory, commercial, financial, and strategic matters. Actual events or results could, of course, differ materially. We refer you to the documents we filed from time-to-time with the SEC, which under the heading Risk Factors, identify important factors that could cause actual results to differ materially from those expressed by the company verbally and in writing today, including without limitation, risks and uncertainties related to product commercial success, market competition, regulatory review and approval processes, conducting clinical trials, compliance with applicable regulatory requirements, our dependence on collaboration partners and the level of cost associated with discovery, product development, business development and commercialization activity.